Back to search
FDAFDA · Food and drugs·Recall number D-0106-2021

Aripiprazole Tablets, USP 15 mg tablets, packaged in a) 1000 count bottle, NDC 60505-2675-8; b) 30 count bottle, NDC 60505-2675-3; Rx Only, Manufactured by: Apotex Inc. Toronto, Ontario Canada M9L 1T9 Manufactured for: Apotex Corp. Weston, Florida 33326

Published November 25, 2020 · Recall initiated: November 11, 2020

Summary

FDA records drug Class II recall D-0106-2021, published November 25, 2020 and initiated November 11, 2020. Recalling firm: Apotex Corp.; Status: Terminated; Reported quantity: a)552 bottles; b) 3192 bottles; Lot: a) PZ6716 Exp. 02/2021; b) PZ6715 Exp. 02/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Dissolution Specifications: Out of specification for dissolution.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Apotex Corp.
Distributor
Distributed Nationwide in the USA
Lot
a) PZ6716 Exp. 02/2021; b) PZ6715 Exp. 02/2021
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Aripiprazole Tablets, USP 15 mg tablets, packaged in a) 1000 count bottle, NDC 60505-2675-8; b) 30 count bottle, NDC 60505-2675-3; Rx Only, Manufactured by: Apotex Inc. Toronto, Ontario Canada M9L 1T9 Manufactured for: Apotex Corp. Weston, Florida 33326 recalled?

Yes. FDA published recall D-0106-2021 on November 25, 2020. Reported hazard: Failed Dissolution Specifications: Out of specification for dissolution.

What should I do if I have this product?

Voluntary: Firm initiated · Letter